Related Experiment Video

Updated: May 15, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Modulation of immunity by antiangiogenic molecules in cancer

Magali Terme1, Orianne Colussi, Elie Marcheteau

  • 1INSERM U970, Paris Cardiovascular Research Center, Université Paris-Descartes, Sorbonne Paris Cité, 56 rue Leblanc, 75015 Paris, France.

Clinical & Developmental Immunology
|January 16, 2013
PubMed

Insights

Anti-angiogenic drugs targeting tumor blood vessel growth also impact immune cells, potentially reversing tumor-induced immunosuppression. Understanding these effects is key for combining anti-angiogenic therapies with immunotherapy and identifying treatment response biomarkers.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Tumor angiogenesis is a key process targeted by new therapeutic drugs.
  • Anti-angiogenic molecules targeting VEGF, VEGFR, PDGFR, and c-kit impact both endothelial and immune cells.
  • Tumors develop immunosuppressive mechanisms to evade the immune system, involving regulatory T cells, myeloid-derived suppressor cells, and cytokines.

Purpose of the Study:

  • To detail the immunomodulatory effects of anti-angiogenic drugs.
  • To explore the potential of combining anti-angiogenic therapies with immunotherapeutic strategies.
  • To identify immune parameters as potential biomarkers for anti-angiogenic therapy response.

Main Methods:

  • Review of existing literature on anti-angiogenic drugs and their effects on the tumor microenvironment.
  • Analysis of immunomodulatory mechanisms affected by anti-angiogenic agents.
  • Discussion of potential combination strategies with immunotherapy.

Main Results:

  • Anti-angiogenic drugs can inhibit tumor-induced immunosuppression by affecting regulatory T cells, myeloid-derived suppressor cells, and immunosuppressive cytokines.
  • These drugs can modulate immune cell function, potentially enhancing anti-tumor immunity.
  • Immune parameters may serve as predictive biomarkers for response or resistance to anti-angiogenic therapies.

Conclusions:

  • Anti-angiogenic drugs possess significant immunomodulatory properties that can counteract tumor immunosuppression.
  • Combination of anti-angiogenic drugs with immunotherapy holds promise for improved cancer treatment outcomes.
  • Monitoring immune parameters during treatment can guide therapeutic decisions and predict patient response.

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Isolation and Culture Expansion of Tumor-specific Endothelial Cells10:15

Isolation and Culture Expansion of Tumor-specific Endothelial Cells

Published on: October 14, 2015

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...